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Abstract
Background: Solitary plasmacytoma (SP) is a localized neoplastic plasma cell disorder with an annual incidence of
less than 450 cases. Given the rarity of this disorder, it is difficult to conduct large-scale population studies.
Consequently, very limited information on the disorder is available, making it difficult to estimate the incidence and
survival rates. Furthermore, limited information is available on the efficacy of various treatment modalities in relation
to primary tumor sites.
Methods: The data for this retrospective study were drawn from the Surveillance, Epidemiology and End Results
(SEER) database, which comprises 18 registries; patient demographics, treatment modalities and survival rates were
obtained for those diagnosed with SP from 1998 to 2007. Various prognostic factors were analyzed via Kaplan-Meier
analysis and log-rank test, with 5-year relative survival rate defined as the primary outcome of interest. Cox
regression analysis was employed in the multivariate analysis.
Results: The SEER search from 1998 to 2007 yielded records for 1691 SP patients. The median age at diagnosis was
63 years. The patient cohort was 62.4% male, 37.6% female, 80% Caucasian, 14.6% African American and 5.4% other
races. Additionally, 57.8% had osseous plasmacytoma, and 31.9% had extraosseous involvement. Unspecified
plasmacytoma was noted in 10.2% of patients. The most common treatment modalities were radiotherapy (RT)
(48.8%), followed by combination surgery with RT (21.2%) and surgery alone (11.6%). Univariate analysis of
prognostic factors revealed that the survival outcomes were better for younger male patients who received RT with
surgery (p < 0.05). Additionally, patients who received neoadjuvant RT had increased survival rates compared to
those receiving adjuvant RT (86% vs 73%, p < 0.05). Furthermore, the analyses revealed that 5-year survival rates for
patients with axial plasmacytoma were superior when RT was combined with surgery (p < 0.05). In the multivariate
analysis, age <60 years and treatment with either RT or surgery showed superior survival rates. Progression to
multiple myeloma (MM) was noted in 551 patients. Age >60 years was associated with a lower 5-year survival in
patients who progressed to MM compared to those who were diagnosed initially with MM (15.1 vs 16.6%). Finally,
those who received RT and progressed to MM still had a higher chance of survival than those who were diagnosed
with MM initially and treated with RT/surgery (21.8% vs 15.9%, p < 0.05).
Conclusions: A review of the pertinent literature indicates that we provided the most comprehensive population-
based analysis of SP to date. Moreover, our study contributes to the establishment of the optimal SP treatment
modality, as RT is the favored option in frontline settings. Consensus is currently lacking regarding the benefits of
combined treatment including surgery. Thus, the findings reported here elucidate the role of primary treatment
modalities while also demonstrating the quantifiable benefits of combining RT with surgery in relation to different
primary tumor sites. While our results are promising, they should be confirmed through further large-scale
randomized studies.
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Background
Multiple myeloma (MM) is a malignant plasma cell
disorder that can result in significant organ damage. In
rare cases, plasma cell proliferation occurs in the form
of a solitary lesion. These presentations can be found
either in bone (leading to what is called solitary bone
plasmacytoma, SBP) or soft tissue (extramedullary plas-
macytoma, EMP), without any evidence of systemic
invasion. It is currently estimated that solitary plasmacy-
toma (SP) accounts for only approximately 5% of all
plasma cell neoplasms that are diagnosed annually [1–3].
Due to the low incidence of this disease, empirical evi-
dence on the clinical course and benefits of various treat-
ment modalities is scarce. This limits the knowledge
needed to determine the best course of action for individ-
ual SP patients. There is a paucity of published works on
cases of SP, and most of those conducted to date have
involved small cohorts, including approximately 50–250
patients [4–8]. Although these studies attempted to define
the prognostic factors and establish appropriate treatment
strategies, they were unsuccessful in identifying the key
aspects that would delay the progression of the disease to
MM. These studies were followed by large population-
based studies conducted in the last decade. For ex-
ample, Dores et al. based their incidence and survival
rate findings on a study of 1500 patients, which is one
of the largest study published to date [9]. Authors of
other population-based studies evaluated either SBP or
EMP in isolation, without conducting comparative
analyses [10, 11].
The treatment guidelines followed by most practitioners
are based on knowledge inferred either from individual
case reports or from series. Currently, radiation therapy
(RT) is typically offered in frontline settings, as SP is a
highly radiosensitive tumor and beneficial outcomes are
expected [12, 13]. However, practitioners are increasingly
considering combining RT with surgery, depending on the
location of the plasma cell proliferation. To date, a con-
sensus has not been reached regarding the role of surgery
in improving survival rates. Recently, Li QW et al. re-
ported that the outcomes yielded by RT alone were super-
ior to those achieved in SP patients who underwent
surgery [14]. However, when interpreting these findings, it
is important to note that their study was conducted at a
single institution and included only 38 SP patients. In
addition, the authors failed to assess the benefits of com-
bined treatment (in which surgery was offered alongside
RT) and to contrast those results with the outcomes of
the aforementioned treatment modalities. At this time, no
data exist on the survival rates of patients who received
adjuvant RT relative to those of patients who were given
neoadjuvant RT along with surgery.
Therefore, to gain a better understanding of the benefits
of RT and surgery in patients with SP and to ascertain the
relative survival rates on a larger scale, we conducted a
retrospective study. The data analyzed and reported in this
work were sourced from the Surveillance, Epidemiology
and End Results (SEER) database, a population-based
registry in the US. By including data pertaining to SP
patients diagnosed in the 1998-2007 period, we have
conducted by far the largest population study involving SP
patients.
Methods
The SEER program was established in 1973 by the
National Cancer Institute (NCI), in accordance with the
National Cancer Act of 1971 [15]. The SEER database
contains information relevant to 18 distinct population
groups registered in 198 US counties and currently con-
tains data on approximately 26% of the overall US popu-
lation. The value of the SEER database stems not only
from the comprehensive population-based records but
also from the detailed information on cancer patients.
Due to its quality and extensiveness, and in particular its
98% case completeness, the SEER database serves as a
benchmark against which other cancer registries are
measured [16].
For the present investigation, using the International
Classification of Disease for Oncology, 3rd Edition (ICD-
O-3) topographical (site and morphology/primary site-
labeled variable) and morphological (site and morphology
ICD-O-3 histology/behavior, malignant variable, 9731/3,
9734/3) codes, we searched the SEER database for SP
cases diagnosed between 1998 and 2007. To meet the
study objectives, we further assessed all identified patient
records, in which we evaluated the SP according to pri-
mary tumor sites, focusing on bone (SPB, topography
codes C40-41) and extramedullary sites (EMP, all topog-
raphy codes excluding C40-41, C80) as the most common
sites. We further classified SBP into appendicular and
axial, while grouping EMP cases into those defined as
upper airway, lower airway, gastrointestinal, central ner-
vous system, skin, connective tissues and lymph nodes,
based on the site of occurrence. It was noted that few
patients were coded as bone marrow (c42.1) or reticulo-
endothelial system (c42.2) as the primary site. However,
the concurrent histology codes were 9732/3, which indi-
cates multiple myeloma. Hence, to avoid bias, a decision
was made to include codes c42.1 and c4.2 along with un-
known sites (c76, c80) in one cohort called P-unspecified.
As part of this investigation, records pertaining to 1691
SP patients in the SEER database were retrospectively
analyzed to obtain information on patient demographics
(age, sex, and ethnicity) and treatment modalities. To
facilitate subsequent analyses, patients were grouped into
four age cohorts (>40, 40-49, 50-59, >60 years). The data
on SP staging were limited, as “local” or “distant” were the
main categories used in the database. In our work,
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patients with “distant” involvement were not of interest,
as by definition, SP is a localized neoplastic growth. Thus,
records pertaining to these patients were excluded from
further analysis. The remaining cohort was analyzed using
the variables “radiation,” “radiation sequence with surgery”
and “Rx-summ.surg.prim.site,” allowing for additional
information on treatment modalities to be sourced from
SEER. Institutional review board approval was not re-
quired for this study, as SEER does not provide any
patient-identifying information.
Statistical analysis
In the present study, the aim was to assess the relative
survival of patients who had undergone different treat-
ment modalities. This primary outcome measure was pre-
sented as the ratio of the overall survival and the expected
survival (within a general population cohort) [17]. Once
this information was obtained, survival curves were gener-
ated by applying the Kaplan-Meier method and were com-
pared using Mantel-Cox log-rank test. One-way analysis
of variance (ANOVA) assisted in the comparison of mul-
tiple groups. A multivariate analysis was employed to
determine the independent prognostic factors using Cox
proportional hazards model. In addition, the disease inci-
dence rates were age-adjusted for the aforementioned four
groups (<40, 40-49, 50-59, >60 years) and were normal-
ized using the 2000 Standard US population. Statistical
analyses were conducted using SEER*Stat Limited Use
software provided by the National Cancer Institute,
Bethesda, Maryland. In addition, GraphPad Prism (Graph-
Pad Software, Inc, La Jolla, California, USA) and IBM
SPSS 20 were employed to analyze and present the data,
in which p < .05 was considered statistically significant.
Results
Demographic characteristics of the patients included in
this retrospective study are summarized in Tables 1 and 2.
The median age at diagnosis was 60.38 ± 14.22 years,
which is 10 years lower than that of the age at diagnosis of
MM. In terms of gender, our patient cohort was not
evenly distributed, as 62% of the patients were male. The
male to female ratio of our cohort was 1.7:1. The cohort
was predominantly Caucasian (80%) followed by African
American (14%) and other races (5.4%). Bone was the
most common site of involvement (57.78%). Additionally,
831 (49%) and 146 (8%) patients had axial and appendicu-
lar skeletal involvement, respectively, while plasma cell
proliferation in soft tissues was noted in 540 patients
(32%). In patients with EMP, the most commonly encoun-
tered site was the upper airway tract (12%).
Table 3 presents the treatment modalities used in
different primary sites and shows that 825 patients (49%)
received radiotherapy and 197 (12%) underwent surgery,
while 359 patients (21%) required both RT and surgery.
In most cases, SP was treated by RT alone, with fewer
patients receiving a combined treatment or surgery only.
We further analyzed the data for patients receiving both
treatment modalities, aiming to establish any differences
in relative survival between those who were given RT in
neoadjuvant vs adjuvant settings.
The overall incidence of plasmacytoma in 2007 was
0.3745/100,000, which indicated a slight increase relative
to the incidence in 2005, which was reported to be
Table 1 Patient demographic characteristics
Base line characteristics Frequency Percent




Sex Male 1056 62.4%
Female 635 37.6%
Race Caucasian 1353 80%




Without Radiation 507 30%
With Radiation 1184 70%
Radiation Sequence Adjuvant 342 20.2%
Neoadjuvant 18 1.1%
Neoadjuvant and adjuvant 5 0.3%
Surgical Intervention No 1135 67.1%
Yes 556 32.9%
Table 2 Distribution of the study population according to the
primary tumor site
Site Number (n) Percentage (%)
Bone (SBP) 977 57.78%
Axial skeleton (c41) 831 49.14%
Appendicular skeleton (c40) 146 8.63%
Extramedullary plasmacytoma(EMP) 540 31.93%
Upper airway tract (Sino-nasal mouth
and pharynx) (c00-14, c33-39)
211 12.48%
Lower airway tract (c32-39) 54 3.19%
Gastrointestinal Tract (c15- 26) 49 2.9%
Soft tissue and connective tissue (c49) 77 4.55%
Central nervous system (c69-72) 49 3.19%
Lymph nodes (c27) 25 1.48%
Skin (c44) 20 1.18%
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0.3462/100,000. The incidence rate ratio of plasmacytoma
for African Americans to Caucasians was calculated, yield-
ing a ratio of approximately 1.25. The prognostic factors of
5-year relative survival are summarized in Table 4. With a
median follow up of 9.7 years, the overall median survival
of the entire cohort was 8.12 years. As seen from the re-
sults, the highest survival rates were noted for the younger
age group (<40 years), while patients aged 60 years or older
had the most unfavorable outcomes (87.45% vs 45%,
p < .05). Moreover, males had a higher chance of survival
than females (63.7% vs 52.9%, p < .05), and more favorable
outcomes were recorded for Caucasians and patients of other
races relative to the African American cohort. However,
these differences were not statistically significant (59.1% vs
57.6%, p= .083) (Additional file 1: Figure S1, S2, S3).
Analyses further revealed that the survival rates of
patients treated with RT were significantly higher than
those of patients who did not receive RT (64.4% vs 48.6%,
p < .05). Moreover, patients who received neoadjuvant RT
had a greater chance of 5-year relative survival than those
Table 3 Radiation and surgical intervention according to primary tumor site




Axial skeleton (c41) 177 (21.3%) 481 (57.88%) 58 (6.98%) 115 (13.84%) 831 (49.14%)
Appendicular skeleton (c40) 30 (20.55%) 78 (53.42%) 15 (10.27%) 23 (15.75%) 146 (8.63%)
Extramedullary plasmacytoma(EMP)
Upper airway tract [Sino-nasal mouth
and pharynx (c00-14, c33-39)]
86 (40.76%) 77 (36.49%) 30 (14.22%) 18 (8.53%) 211 (12.48%)
Lower airway tract (c32-39) 5 (9.26%) 19 (35.19%) 9 (16.67%) 21 (38.89%) 54 (3.19%)
Gastrointestinal Tract (c15- 26) 2 (4.08%) 11 (22.45%) 24 (48.98%) 12 (24.49%) 49 (2.9%)
Soft tissue and connective tissue (c49) 10 (12.99%) 33 (43.86%) 10 (12.99%) 24 (31.17%) 77 (4.55%)
Central nervous system (c69-72) 17 (34.69%) 15 (30.61%) 16 (32.65%) 1 (2.04%) 49 (3.19%)
Lymph nodes (c27) 10 (40%) 5 (20%) 5 (20%) 5 (20%) 25 (1.48%)
Skin (c44) 4 (20%) 6 (30%) 8 (40%) 2 (10%) 20 (1.18%)
All other sites (c48,50,53,56,67,68,73,74) 7 (12.73%) 14 (25.45%) 20 (36.36%) 14 (25.45%) 55 (3.25%)
Plasmacytoma Unspecified (P-unspecified) 11 (6.67%) 86(49.41%) 2 (1.21%) 75 (43.11%) 174 (10.28%)
Total 359 (21.23%) 825 (48.79%) 197 (11.65%) 310 (18.33%) 1691 (100%)
Table 4 Variable analyses of prognostic factors
Characteristics Over all 5 years relative survival Over all mean survival P value
% 95% CI Month 95% CI
Age >40 87.4 80 – 92.2 149.87 139.88 – 159.86 <0.05
40-49 78.6 72.4 – 83.6 130.16 120.96 – 139.35
50-59 73.2 67.9 – 77.7 119.70 112.56 – 126.84
≥60 45 41.1 – 48.7 62.56 58.25 – 66.87
Sex Male 63.7 60.2 – 66.9 97.03 92.35 – 101.7 <0.05
Female 52.9 48.3 - 57.2 80.86 75.34 – 86.38
Race White 59.1 56 – 62.1 90.73 86.65 – 94.81 0.083
Black 57.6 50.3 – 61.2 84.52 75.78 – 93.27
Others 72.9 61.1 – 81.6 111.97 96.59 – 127.36
Exposure To Radiotherapy Without Radiation 48.6 43.6 – 53.4 74.59 67.93 – 81.26 <0.05
With Radiation 64.4 61.1 – 67.5 98.9 94.59 – 103.21
Radiation Sequence Adjuvant 72.5 66.5 – 77.6 115.12 107.43 – 122.82 <0.05
Neoadjuvant 86.2 55 – 96.4 132.33 103.73 – 160.92
Neoadjuvant and adjuvant 62.8 11.5 – 90.5 72.4 38.95 – 105.85
Surgical Intervention No 54.7 51.3 – 57.9 81.58 77.2 – 85.97 <0.05
Yes 69.7 65.1 – 73.8 111.37 105.11 – 117.63
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who received adjuvant RT (86% vs 73%, p < .05). A signifi-
cant difference in survival outcomes was also observed in
patients who underwent surgery when compared to their
counterparts who did not (69.7% vs 57.4%), P <0.05) (Figs. 1,
2 and 3). After analyzing the 5-year relative survival of dif-
ferent treatment modalities in relation to primary site, we
noted that patients with axial skeletal involvement treated
with a combination of RT and surgery had a higher survival
rate (70.5%) than those who received only RT (61.5%) or
surgery alone (46.4%) (p < .05) (Table 5). Patients with
upper and lower airway tract involvement had a higher
survival with surgery alone when compared to combination
therapy and RT (96.7%, 100% p <0.05 and p < 0.01, respect-
ively). Patients with involvement of the appendicular
skeleton (63.6%), central nervous system (92.6%) and other
sites (excluding GI, skin and connective tissues, lymph
nodes) (64.4%) had an increased survival rate when treated
with radiation alone (p = 0.024, p < .05, p 0.004, respect-
ively). In contrast, patients diagnosed with soft tissue EMP
and lymph node EMP attained better survival outcomes
when given combination treatment. However, it should be
noted that the differences were not statistically signifi-
cant (p = 0.69, p = 0.83, respectively) (Table 5).
In the multivariate Cox regression analysis of the prog-
nostic factors, we found that age < 60 years (HR 0.38,
95% CI 0.330-0.445, p < 0.001) and treatment with either
RT (HR 0.597, p < 0.001) or surgery (HR 0.764 p < 0.001)
were all independent predictors of higher overall sur-
vival. Combination therapy did not appear to be signifi-
cant in the multivariate analysis (HR 1.226, 95% CI
0.966-1.552, p = 0.094) (Table 6).
To evaluate plasmacytoma as a localized disease with
cases progressing to myeloma, information on the survival
and cause of death was obtained regarding all cases of mul-
tiple myeloma during the years 1998–2007 (17,405 cases).
It was noted that 553 patients (32.7%) had progressed to
MM during the median follow-up of 9.7 years. Of these pa-
tients, 72% were > 60 years, 56.6% were male, and 81.2%
were Caucasian (Additional file 2: Table S1). Additionally,
70% of patients who progressed to myeloma had received
RT and 26.4% had received surgical intervention. We found
that there was a significant difference in 5-year survival be-
tween patients >60 years who were initially diagnosed with
MM compared to those initially diagnosed with plasmacy-
toma and who subsequently progressed to MM (16.6% vs
15.1%, p < 0.031). An increased 5-year survival was noted in
males, Caucasians and those who received RT among
patients initially labelled as SP who later progressed to MM
when compared to those with an initial diagnosis of
MM (22.2% vs 18%, 18.4% vs 17.5%, 21.8% vs 15.9%
and p < 0.09, p < 0.018, p < 0.05, respectively) (Table 7).
Discussion
MM is a systemic plasma cell disorder accounting for
1.5% of all cancers and contributing up to 13% of all
hematologic malignancies worldwide. SP, while rare, is
categorized as an independent subset of plasma cell
disorders manifested through localized proliferation of
neoplastic monoclonal cells. Despite some notable simi-
larities between SP and MM in terms of their cytological
and immunophenotypic characteristics, these tumors are
differentiated by their site predilection and mortality
rates. An extensive body of literature on MM exists;
thus, its pathogenesis, epidemiology, and response to
various treatments has been comprehensively investi-
gated. In contrast to MM, SP has been the subject of
Fig. 1 Kaplan-Meier survival curve comparing patients who received RT vs. no RT
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limited research to date. Consequently, and due to its
low incidence, current SP treatment guidelines are based
on the findings of a limited number of retrospective
studies involving small samples. Empirical evidence con-
firms the benefit of RT in SP patients. However, consen-
sus regarding the effectiveness of surgery is presently
lacking. A search of the SEER database revealed that
more than 1600 patients were diagnosed with SP from
1998 to 2007 in the present investigation. In this study,
which is, to the best of our knowledge, the largest popula-
tion study reported to date, we aimed to assess the sur-
vival patterns according to age, gender, site of involvement
Fig. 2 Kaplan-Meier survival curve comparing patients who received surgery vs. those that did not
Fig. 3 Kaplan-Meier survival curve comparing sequence of RT in patients who received RT and surgery
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and treatment modality as well as to examine the disease
progression to myeloma.
Given the low incidence of SP, the diagnostic criteria
have been difficult to establish and have been modified
throughout the years. The current guidelines provided
by the International Myeloma Working Group (IMWG
2013) define SP as biopsy-confirmed plasma cell prolif-
eration in the bone or soft tissue in the presence of
normal bone marrow and a normal skeletal survey
(except for the primary solitary lesion) [18]. Guidelines
also recommend using the term SP with minimal bone
marrow involvement when there is < 10% plasma cell
proliferation in bone marrow in the presence of a con-
firmed solitary lesion elsewhere. These guidelines are
highly helpful, as the opinions of specialists regarding
the threshold for diagnosing SP with marrow involve-
ment previously differed, ranging from 5% to 10% of
plasma cell proliferation in marrow [1, 2]. Although >
10% plasma cell proliferation in bone marrow has always
been indicative of MM, there had been no mention of
the minimum percentage required for the diagnosis in
prior IMWG guidelines (2003). These differences in
opinion are noteworthy, as our study sample included
patients who were diagnosed prior to the introduction of
the 2013 IMWG guidelines, which resulted in a mis-
classification of some cases in which bone marrow was
coded as the primary site. In addition, there is also the
potential for misdiagnosed MM. Hence, to avoid propa-
gating these errors in our findings, patients who were
coded as bone marrow (c42.1), reticulo-endothelial sys-
tem (c42.2) and unknown (c 76, c 80) were combined
into one cohort, called P-Unspecified. In their study,
Dores et al. introduced a similar cohort, in which all
cases coded to bone marrow and unknown sites were
also grouped under a P-unspecified category [9].
Our analyses revealed that SBP primarily involves the
axial skeleton. This finding supports previously reported
results, which suggested that SBP is frequently observed
in marrow-containing bones, specifically vertebrae [19].
In addition, and in accordance with the findings re-
ported by Patel et al., we found when analyzing our sam-
ple that the upper airway tract, including the sinuses,
which have extensive lymphatic supply, was the most
commonly involved EMP site [20].
Prior population studies have revealed a male predom-
inance in the SP cohort. Our findings concur with this
conclusion, with a male-to-female ratio of 1.6:1 [4, 20].
In existing studies focusing primarily on SBP, the male-
to-female ratio was in the range of 1.5–2.4 [5, 6]. How-
ever, among EMP patients, a 3:1 male predominance
was previously observed in sites involving upper airway
tract [5, 20]. We also noted a gender bias in the survival
rates, in which males achieved significantly better out-
comes than females (64.1% vs 53.8%, p < 0.05). Previous
research, however, did not offer conclusive findings in
this respect, as men with SP showed an increased chance
of survival in some studies, while no gender-related
differences were reported in others [5, 9].
The majority of the patients included in our retro-
spective study were Caucasian, followed by African
American and other races. Our results concur with those
Table 5 Five year relative survival pertaining to different treatment modalities according to the primary tumor site
Site Relative survival p Value
Both (%) Radiation only (%) Surgery only (%) Neither rad. nor surgery (%)
Bone (SBP)
Axial skeleton (c41) 70.50% 61.20% 46.4% 36.90% < .05
Appendicular skeleton (c40) 54.00% 63.6% 37.8% 32.5% .024
Extramedullary plasmacytoma(EMP)
Upper respiratory tract[sinonasal mouth
and pharynx (c00-14, c33-39)]
93.30% 73.8% 96.7% 45.1% < .05
Lower respiratory tract (c32-39) 95.0% 42.3% 100% 33.5% .001
Gastrointestinal Tract (c15-26) 0.00% 33.7% 71.6% 28.0% .057
Soft tissue and connective tissue (c49) 61.3% 50.9% 43.2% 38.1% .346
Central nervous system (c69-72) 67.8% 92.6% 52.9% 0.00% < .05
Lymph nodes (c27) 74.8% 83.9% 63.0% 100.0% .836
Skin (c44) 89.5% 90.6% 91.0% 100.0% .692
All other EMP sites(c48,50,53,56,67,68,73,74) 31.1% 64.4% 62.3% 28.6% .004
Table 6 Cox proportional hazards model for prognostic factors
Variables Hazard ratio 95% CI P value
Lower Upper
Age <60 years 0.380 0.330 0.440 >0.001
radiation sequence with surgery 1.226 .966 1.557 .094
Radiation 0.597 0.522 0.684 >0.001
Surgery 0.746 0.693 0.802 >0.001
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reported by Dores et al. and Jawad et al., who noted that
the SP incidence rates were notably higher among
African Americans than among Caucasians (IR 0.6 vs
0.4) [9, 10]. Authors of other studies focusing on MM
also reported the same racial distribution [21, 22]. This
observation might point to differences in genetic suscep-
tibility between different races. However, when analyzing
the SEER sample, no racially biased survival advantages
could be found. When interpreting this finding, it is
important to acknowledge the limited data on survival
differences in different racial groups. Thus, further studies
are warranted to confirm our findings.
SP affects primarily those above 40, and its incidence
increases with age. In our sample, the median age at SP
diagnosis was 60 years, with a standard deviation of 14
years, which is consistent with previous reports. Our
analyses further revealed that the survival rates were in-
versely related to age. Specifically, the highest and lowest
chances of survival were observed for the <40 and >60
age cohorts, respectively. In accordance with the find-
ings of previous retrospective studies reported by Knobel
et al. and Jawad et al., we found that older age (>60
years) was a prognostic factor of poor outcomes in both
the univariate and multivariate analyses in terms of over-
all survival and progression to MM [5, 10]. There could
be various reasons for this observation. In patients who
progress to MM, it is possible that older patients are
treated with less aggressive therapies and are less in-
volved in clinical trials compared to younger patients
[5]. That being said, it remains a challenge to identify an
exact reason why patients > 60 years develop MM more
frequently than younger patients.
As SP is a highly radiosensitive tumor, most patients
undergo RT as the first line of treatment, resulting in
an excellent local control rate. In several retrospective
studies, RT was found to be more effective than both
surgery and chemotherapy as the sole treatment modality
[5, 12, 13, 23]. In our study, an improved overall survival
was noted in patients who received RT in both the univar-
iate and multivariate analyses (Table 4). This was not in
accordance with results reported by Jawad et al. and
Knobel et al. [5, 10]. However, a recent retrospective study
by Finsinger et al., who evaluated 53 patients, found there
was a significant difference in progression-free survival
(PFS) between patients who received RT and those who
received other treatment modalities [24]. Despite the
excellent local control, in our study, at least 70% of pa-
tients who received RT progressed to myeloma. Our study
series also revealed that despite progressing to myeloma,
patients who received RT still had a higher chance of
survival than those who were diagnosed with MM initially
and exposed to RT. To date, there are no set guidelines on
the dose of RT and its effects on local control and progres-
sion of the disease. Some authors suggest using doses of
40-50 Gy for lesions smaller than 5 cm and >50 Gy for
lesions >5 cm [5, 12, 23]. Tsang et al. reported that there
was no evidence of improvement with RT doses > 30-35
Gy in terms of achieving local control [25]. We could not
Table 7 Multivariate analysis of 5 year survival of the patients diagnosed with plasmacytoma who progressed to myeloma & those
with initial diagnosis of Myeloma
Characteristics Plasmacytoma Myeloma P value
% 95% CI % 95% CI
Age >40 54.3% 24.9 – 76.5 31.2% 24.8 – 37.7 0.06
40-49 34% 19.6 – 48.9 23% 20.5 – 25.6 0.12
50-59 24.6% 16.5 – 33.5 23.5% 21.9 – 25.1 0.27
≥60 15.1% 11.4 – 19.3 16.6% 14.8 – 18.4 0.031
Sex Male 22.2% 17.3 – 27.4 18% 17.2 – 18.9 0.009
Female 15.9% 11.2 – 21.2 16.9% 16 – 17.8 0.102
Race White 18.4% 14.6 – 22.4 17.5% 16.8 – 18.3 0.018
Black 23% 14.1 – 33.3 17.6% 16.2 – 19.2 0.085
Others 27.1% 9.7 – 48.2 15.4% 14 – 19 0.104
Exposure To Radiotherapy Without Radiation 13.6% 8.5 – 19.9 18% 17.3 – 18.8 0.062
With Radiation 21.8% 17.5 – 26.5 15.9% 14.7 – 17.1 <0.05
Radiation Sequence Adjuvant 22.4% 14.1 – 31.9 18.8% 12.4 – 26.3 0.096
Neoadjuvant 100% N/a 0% N/a N/a
Neoadjuvant and adjuvant 0% N/a 0% N/a N/a
Surgical Intervention No 18.5% 14.5 – 22.8 17.5% 16.8 – 18.1 0.080
Yes 22.1% 15.4 – 29.7 19.6% 12.7 – 27.7 0.119
N/a Not applicable
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study the correlation between RT dose and local failure or
progression to MM in our patients due to a lack of infor-
mation in the SEER database.
Surgery for SBP patients is suggested only when they
present with limb-threatening situations, such as cord
compression or impending fracture. However, some
authors believe that high-dose RT combined with sur-
gery achieves a better progression-free survival relative
to RT alone in SBP patients [26]. Bataille et al. and
Frassica et al. reported higher rates of local failure in pa-
tients with vertebral lesions who were treated with RT
only [8, 27]. These assertions were confirmed in our
study, as the analyses revealed greater survival rates in
patients with axial skeletal involvement treated with RT
along with surgery when compared to those who under-
went RT only or surgery alone.
Experts have yet to reach a consensus regarding the
optimal treatment modality for EMP. Current guidelines
stipulate that head and neck EMP be treated with RT
only, as surgical resection of these tumors can be highly
invasive [23]. However, when EMP is located in other
areas, surgical resection is recommended and should be
followed by RT only if the surgical margins are inad-
equate [28]. Sasaki et al. noted that patients who under-
went surgery combined with adjuvant radiotherapy had
superior survival outcomes than those receiving RT or
surgery as stand-alone treatment [29]. In contrast,
Alexiou et al. reported evidence indicating that offering
surgery alone to EMP patients was the most beneficial
treatment mode when negative surgical margins could
be achieved [7]. Our analysis showed that patients with
airway tract involvement (upper and lower) had overall
improved survival outcomes with surgery as opposed to
combination therapy with RT and surgery. The univari-
ate and multivariate analyses in this study showed a
significant survival advantage associated with surgery
alone for SP. This result reflects the fact that we evalu-
ated both SBP and EMP together as one cohort. It is
unclear if the same holds true when SBP and EMP are
studied individually. Furthermore, when analyzing pro-
gression to myeloma, surgical intervention did not
improve survival rates. Considering the findings reported
here together with the aforementioned studies, it can be
asserted that for EMP patients, the best treatment
modality remains elusive. Thus, further randomized
controlled studies must be conducted to gain more in-
formation on this disease and the treatment outcomes.
We also found that among the SP patients who re-
quired both surgery and RT, those who received RT in
the neoadjuvant setting had higher survival rates than
those who were given RT in the adjuvant setting. This
comparison, however, lacked sufficient statistical power,
as only a few patients had received neoadjuvant RT. This
may suggest the presence of a large tumor, requiring
shrinkage prior to surgery, thus increasing the likelihood
of efficacy of neoadjuvant chemotherapy. Chemotherapy,
although not a standard of care, has been suggested by
some authors. There has been only one relevant pro-
spective trial thus far, and it evaluated the benefit of
chemo radiotherapy in 53 patients. Although the study
included a limited number of patients, it concluded
that combination therapy increased survival duration
as well as remission [30]. Kumar et al. presented in a
series of 25 SBP patients that angiogenesis was highly
associated with disease progression to myeloma [31].
Therefore, targeting angiogenesis with agents such as
thalidomide represents a new therapeutic approach for
patients with SBP.
Although, high local control rates are achieved with
RT and/or surgery, progression to myeloma is still fre-
quent. In our study, the cause of death in 33% of pa-
tients diagnosed with SP was progression to MM. Soutar
et al. reported that SBP progressed to MM in >75% of
cases [23]. As our cohort included both SBP and EMP,
this number appears to be lower. There is no clear
evidence on the factors predicting the progression of SP
into myeloma. This lack of definitive evidence is attrib-
uted to the low incidence of the disease and the lack of
randomized controlled studies. A few researchers con-
sider age, size of the tumor, and persistence of M protein
after treatment as factors indicating a worse prognosis.
In our study, we found only age >60 to be a significant
prognostic factor of progression to myeloma. As no in-
formation was available in the database regarding prior
medical history, laboratory work-up and radiologic
evaluation, our study could not analyze the prognostic
significance of tumor size, number of lesions and persist-
ence of M protein after treatment and accuracy of MRI.
The strengths of our study stem from the analysis of
reliable population-based data, ensuring that our find-
ings can be generalized to the US population. In addition
to providing representative findings, we studied the effi-
cacy of primary treatment modalities in relation to dif-
ferent sites, which can provide guidelines for clinical
practice. However, it is also important to note the study
limitations, one of which was the inability to review the
pathology of cases and to determine the extent of bone
marrow or other organ involvement (anemia, renal
insufficiency). As this was a retrospective study, the ac-
curacy of the data was beyond our control, and there is
also the possibility that in some cases, MM was misclas-
sified as plasmacytoma. However, as our analysis period
ranged from 1998 to 2007, this choice reduced the likeli-
hood of misclassification, as sensitive diagnostic testing
with MRI and monoclonal paraproteins was widely avail-
able at the time. Nonetheless, to avoid potential biases,
we combined the records of patients with tumors coded
to bone marrow and unspecified sites into a single
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cohort, denoted P-Unspecified, and assessed them separ-
ately from other groups. Another noteworthy limitation
stems from the absence of information on the chemo-
therapy regimens used in the adjuvant setting. This
omission prevented us from determining the survival
benefit derived from chemotherapy, if any. Lastly, we
could not study the effects of other prognostic factors
such as tumor size and presence of M protein after
treatment in progression of SP to MM.
Conclusion
The role of surgery in SP treatment remains controver-
sial due to the incongruent findings reported by a lim-
ited number of studies. Based on our large population
study, we conclude that therapy of combined RT with
surgery is beneficial in axial plasmacytoma. Although
increased survival rates were observed for patients
treated with RT or surgery, disease progression to mye-
loma was still evident. Large prospective trials are
needed to establish sound evidence on the prognostic
factors associated with disease progression. Furthermore,
the efficacy of the use of adjuvant chemotherapy should
be established in phase II or III trials. Although our find-
ings are highly informative, they should be confirmed
with further randomized trials.
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